Literature DB >> 6295182

Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture.

J Penit, M Faure, S Jard.   

Abstract

Rat aortic smooth muscle cells were isolated and maintained in primary culture. After 2-3 days, cells recovered their contractile phenotype and could be induced to contract in response to vasopressin and angiotensin II. Vasopressin- and angiotensin-specific binding sites were detected on these cells, using tritiated Lys8-vasopressin, Asn1-Val5-angiotensin II, and Sarc1-Ile8-angiotensin II. Vasopressin binding sites had Kd values of 30 and 12 nM for Lys8-and Arg8-vasopressin, respectively, and a maximal binding capacity of 25,000 sites/cell. They displayed several of the expected characteristics of vasopressin receptors involved in the vasopressor response in vivo. A highly significant correlation was found between the relative agonistic or antagonistic vasopressor potencies of a series of vasopressin structural analogues and their relative abilities to inhibit [3H]vasopressin binding to aortic smooth muscle cells. Specific binding sites for Asn1-Val5-angiotensin II and Sarc1-Ile8-angiotensin II had the following characteristics: Kd = 2.3 and 1.3 nM, respectively; maximal capacity: 50,000 sites/cell. Vasopressin and angiotensin did not modify the intracellular cyclic AMP content of aortic smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6295182     DOI: 10.1152/ajpendo.1983.244.1.E72

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  23 in total

1.  Characterization of specific V1a vasopressin-binding sites on a rat mammary-tumour-cell line.

Authors:  G Guillon; C J Kirk; M N Balestre
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

2.  Characterization of human platelet vasopressin receptors.

Authors:  M Thibonnier; J M Roberts
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

3.  Vasopressin modulates the spontaneous electrical activity in aortic cells (line A7r5) by acting on three different types of ionic channels.

Authors:  C Van Renterghem; G Romey; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Authors:  David E Lanfear; Hani N Sabbah; Steven R Goldsmith; Stephen J Greene; Andrew P Ambrosy; Angela J Fought; Mary J Kwasny; Karl Swedberg; Clyde W Yancy; Marvin A Konstam; Aldo P Maggioni; Faiez Zannad; Mihai Gheorghiade
Journal:  Circ Heart Fail       Date:  2012-12-12       Impact factor: 8.790

5.  Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor.

Authors:  R C Gaillard; P Schoenenberg; C A Favrod-Coune; A F Muller; J Marie; J Bockaert; S Jard
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

6.  [Cardiovascular effect of the antidiuretic hormone arginine vasopressin].

Authors:  W Rascher
Journal:  Klin Wochenschr       Date:  1985-10-01

7.  Specific vasopressin binding to rat adrenal glomerulosa cells. Relationship to inositol lipid breakdown.

Authors:  G Guillon; N Gallo-Payet
Journal:  Biochem J       Date:  1986-04-01       Impact factor: 3.857

8.  Vasopressin-stimulated [3H]-inositol phosphate and [3H]-phosphatidylbutanol accumulation in A10 vascular smooth muscle cells.

Authors:  R Plevin; A Stewart; A Paul; M J Wakelam
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

Review 9.  Vasopressin receptor antagonists: from pivotal trials to current practice.

Authors:  Ankur Kalra; Valmiki Maharaj; Steven R Goldsmith
Journal:  Curr Heart Fail Rep       Date:  2014-03

10.  Angiotensin II rapidly increases phosphatidate-phosphoinositide synthesis and phosphoinositide hydrolysis and mobilizes intracellular calcium in cultured arterial muscle cells.

Authors:  J B Smith; L Smith; E R Brown; D Barnes; M A Sabir; J S Davis; R V Farese
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.